Shut Down

WuXi NextCODE Stock

Using genomic information to improve health

Sign up today and learn more about WuXi NextCODE Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Nexus Investment Ventures


Cambridge MA, US

Total Funding


About WuXi NextCODE Stock

WuXi NextCODE is a fully integrated contract genomics organization building the global standard platform for genomic data. With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we serve the leading population genomics, precision medicine, diagnostics and wellness initiatives and enterprises using the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi Group company.


Funding History

October 2013$15.0M
May 2017$75.0M
September 2017$165M
November 2018$200M



Hannes Thor Smárason

President and Chief Scientific Officer

Jeffrey Gulcher

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: